R. Jordan

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
R. Jordan, R.e. Jordan, Robert E. Jordan, R. E. Jordan, Robert E Jordan, Robert Jordan, R E Jordan, R Jordan
Publication record
87 papers · 4,345 citations · H-index 32

PAPERS

Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions
20224 citationsauthor #11
Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo
201818 citationsauthor #3
Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy
20184 citationsauthor #1
Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function
20162 citationsauthor #2
A peptide immunization approach to counteract a Staphylococcus aureus protease defense against host immunity.
20168 citationsauthor #1
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
2015186 citationsauthor #6
Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
2015116 citationsauthor #14
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions
201544 citationsauthor #4
Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity
201517 citationsauthor #10
Abstract 638: Modulation of antibody-dependent cytokine release using Fc engineering
20150 citationsauthor #4
A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo
201430 citationsauthor #12
Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge
201416 citationsauthor #8
A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies
201419 citationsauthor #10
Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions*
201341 citationsauthor #10
Abstract 4327: A novel protease resistant antibody platform with selectable cell killing functions.
20130 citationsauthor #5
Anti-Tumor Function Invasion while Retaining Fc-Dependent Tumor-Associated Macrophages Promote
20120 citationsauthor #10
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
20121 citationsauthor #9
Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
2012109 citationsauthor #11
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
201262 citationsauthor #9
Galactosylation variations in marketed therapeutic antibodies
2012124 citationsauthor #2
The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge
201142 citationsauthor #4
The Origins, Specificity, and Potential Biological Relevance of Human Anti-IgG Hinge Autoantibodies
201128 citationsauthor #3
Cleavage of IgGs by proteases associated with invasive diseases
2010151 citationsauthor #2
Glyco-engineering of Fc Glycans to Enhance the Biological Functions of Therapeutic IgGs
20102 citationsauthor #3
A synthetic peptide approach for elucidating the points of natural auto-antibody reactivity to proteolytic fragments of human IgG.
20094 citationsauthor #3
Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge
200992 citationsauthor #10
Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs1
200847 citationsauthor #11
Proteolytically Inactivated IgGs Reconstitute the Effector Functions of Human Anti-IgG1 Hinge Autoantibodies
20080 citationsauthor #1
Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid.
2008114 citationsauthor #6
Human Anti-IgG 1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs 1
20084 citationsauthor #1
Interference with Tissue Factor Prolongs Intrahepatic Islet Allograft Survival in a Nonhuman Primate Marginal Mass Model
200776 citationsauthor #9
THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION
20072 citationsauthor #1
EFFECT OF INHIBITION OF TISSUE FACTOR ON NONHUMAN PRIMATE ISLET ALLOGRAFT SURVIVAL
20061 citationsauthor #7
Formation in Primates With Monoclonal Antibodies
20050 citationsauthor #5
Pharmacodynamic enhancement of the anti-platelet antibody Fab abciximab by site-specific pegylation
200420 citationsauthor #2
Ticlopidine Enhances the Platelet Inhibitory Capacity of Abciximab In Vitro
20045 citationsauthor #3
Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibodyof c7E3 Fab (abciximab; ReoProTM)
200429 citationsauthor #3
Pharmacokinetics (PK), pharmacodynamics (PD) and GPIIB/IIIA receptor blockade of ABCIXIMAB in stable angina pectoris patients
20040 citationsauthor #6
Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.
20023 citationsauthor #6
Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates.
200234 citationsauthor #5
An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates
200291 citationsauthor #6
Abciximab Pharmacodynamics Are Unaffected by Antecedent Therapy with Other GPIIb/IIIa Antagonists in Non-Human Primates
20024 citationsauthor #5
Abciximab Readministration: Results of the ReoPro Readministration Registry
2001137 citationsauthor #8
7E3 F(ab’)2, an Effective Antagonist of Rat αIIbβ3 and αvβ3, Blocks In Vivo Thrombus Formation and In Vitro Angiogenesis
200127 citationsauthor #6
Effect of Ca2+ Chelation on the Platelet Inhibitory Ability of the GPIIb/IIIa Antagonists Abciximab, Eptifibatide and Tirofiban
200135 citationsauthor #2
7E3 F(ab')2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3, blocks in vivo thrombus formation and in vitro angiogenesis.
200111 citationsauthor #6
Appendix Participating Institutions , Principal Investigators , and Study Coordinators
20010 citationsauthor #8
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
200047 citationsauthor #6
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
200018 citationsauthor #8
Pharmacological differentiation of GP IIb/IIIa inhibitors
19997 citationsauthor #1
Current Antiplatelet Therapy
19993 citationsauthor #2
Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist
19992 citationsauthor #1
The role of GP IIb/IIIa inhibitors on the fibrinolytic resistance of platelet-fibrin thrombi
19990 citationsauthor #2
Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and (cid:97) v (cid:98) 3 Integrins
19981 citationsauthor #3
Synergy of abciximab and ticiopidine in patients undergoing intracoronary stenting
19981 citationsauthor #10
Abciximab Can Freely Redistribute Between GPIIb/IIIa and Î±v/Î²3
19982 citationsauthor #4
Abciximab reveals rapid ligand uptake systems in platelets
19980 citationsauthor #6
Safety of readministration of abciximab; interim results of the ReoPro readministration registry (R3)
199811 citationsauthor #7
Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins
1998256 citationsauthor #3
Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer
199816 citationsauthor #1
Abciximab inhibits release of platelet granule constituents
19982 citationsauthor #4
Abciximab can freely redistribute between GPIIb/IIIa and alphavbeta3
19980 citationsauthor #4
Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
199892 citationsauthor #3
2.P.324 Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)
19970 citationsauthor #5
Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes
19979 citationsauthor #2
PD 165929 - The First High Affinity Non-Peptide Neuromedin-B (NMB) Receptor Selective Antagonist.
19979 citationsauthor #7
7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli.
199755 citationsauthor #5
Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
1997110 citationsauthor #8
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.
1996487 citationsauthor #6
PD 165929 — the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist
199632 citationsauthor #7
Rapid assessment of platelet inhibition using a modified whole blood aggregometer (aggrestat™) in PTCA patients receiving ReoPro™
19964 citationsauthor #6
Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor.
19958 citationsauthor #3
Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): Potent dose-dependent inhibition of platelet function
19954 citationsauthor #2
Method of reducing the immunogenicity of the variable regions of antibodies
19930 citationsauthor #1
Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents a
1991165 citationsauthor #7
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
1990194 citationsauthor #7
Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors.
1989265 citationsauthor #5
Physiological variant of antithrombin‐III lacks carbohydrate sidechain at Asn 135
1987103 citationsauthor #3
THE PHYSIOLOGICAL ANTITHROMBIN (BETA) VARIANT WITH INCREASED HEPARIN AFFINITY LACKS CARBOHYDRATE AT ASN 135
19872 citationsauthor #4
Neonatal Lupus Erythematosus: A Report of Three Cases Associated with Anti-Ro/SSA Antibodies
198616 citationsauthor #5
RESOLUTION OF TWO FORMS OF HUMAN ANTITHROMBIN III BY AFFINITY CHROMATOGRAPHY ON IMMOBILIZED HEPARIN
19830 citationsauthor #3
Heparin with two binding sites for antithrombin or platelet factor 4.
198294 citationsauthor #1
Preparation Of Antithrombin, High Activity Heparin And A Heparin-Antithrombin Complex By A Rapid Two-Step Affinity Method
19810 citationsauthor #1
The binding of low molecular weight heparin to hemostatic enzymes.
198076 citationsauthor #1
The interaction of heparin with thrombin and antithrombin.
198027 citationsauthor #3
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin.
1980289 citationsauthor #1
Fractionation of low molecular weight heparin species and their interaction with antithrombin.
1979176 citationsauthor #3

TIMELINE

1979 176 citations

1980 392 citations

1981 0 citations

1982 94 citations

1983 0 citations

1986 16 citations

1987 105 citations

1989 265 citations

1990 194 citations

1991 165 citations

1993 0 citations

1995 12 citations

1996 523 citations

1997 183 citations

1998 381 citations

1999 12 citations

2000 65 citations

2001 210 citations

2002 132 citations

2004 54 citations

2005 0 citations

2006 1 citations

2007 78 citations

2008 165 citations

2009 96 citations

2010 153 citations

2011 70 citations

2012 296 citations

2013 41 citations

2014 65 citations

2015 363 citations

2016 10 citations

2018 22 citations

2022 4 citations

COAUTHOR MAP

CONCEPT FOOTPRINT